We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

If you ever find yourself staring down this venomous Texas dweller, be careful. Statistics strongly suggest that it's better ...

Eli Lilly’s Q1 earnings smashed expectations, fueled by surging demand for its blockbuster drugs Zepbound and Mounjaro. The ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eli Lilly's stock dropped by 10.14% even though the company reported strong earnings for the first quarter. The ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly's first-quarter results were driven by exceptional sales of its diabetes treatment, Mounjaro, and weight loss drug, Zepbound. Mounjaro achieved $3.84 billion in revenue, a remarkable 113% ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...